Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima - Japan
Author Profile
GOOGLE SCHOLAR
🎓 Early academic pursuits
Sho Horikoshi’s journey into the field of neuropsychiatry began with his education at kitasato university, school of medicine, where he graduated in march 2011. his passion for psychiatry led him to complete his initial residency at nerima general hospital in april 2011. driven by a deep interest in understanding the complexities of mental health, he joined the department of neuropsychiatry at fukushima medical university in april 2013. these formative years provided him with a strong foundation in clinical practice and research, shaping his future contributions to psychiatric medicine.
🚀 Professional endeavors
Horikoshi’s professional career has been marked by a series of significant roles in both academic and clinical settings. after gaining extensive experience at hoshi general hospital and hoshigaoka hospital, he completed his doctoral program at fukushima medical university in march 2017. shortly after, he took on the role of assistant professor in the department of neuropsychiatry, further advancing his expertise in the field. his dedication to patient care led him to ichiyokai hospital in 2019, where he contributed to improving mental health services. later that year, he became the chairman and director of horikoshi mental & physical clinic under sukoyaka medical corporation, solidifying his leadership in psychiatric healthcare. in april 2023, he expanded his academic influence by becoming a clinical associate professor at fukushima medical university and a part-time lecturer at tohoku university’s graduate school of medicine.
🧐 Contributions and research focus
Horikoshi’s research focuses on the intersection of neuropsychiatry and clinical applications, with a strong emphasis on advancing mental health treatments and understanding psychiatric disorders. his work has significantly contributed to the development of innovative therapeutic strategies, addressing complex mental health challenges. he has actively integrated clinical Clinical Psychopharmacology research with patient-centered care, ensuring that advancements in neuropsychiatric treatments translate into real-world benefits. his expertise spans various aspects of mental health, from mood disorders and schizophrenia to the impact of neurological conditions on psychiatric well-being.
🏆 Accolades and recognition
Throughout his career, horikoshi has received widespread recognition for his contributions to neuropsychiatry. his role as a clinical associate professor and part-time lecturer reflects his Clinical Psychopharmacology esteemed reputation in academic circles. his dedication to mental health research and clinical excellence has made him a respected figure in psychiatric medicine. his leadership at horikoshi mental & physical clinic has also gained recognition for improving access to specialized mental healthcare and implementing innovative treatment approaches.
👨💻 Impact and influence
Horikoshi’s influence extends beyond academic research and clinical practice. his leadership in psychiatric institutions has transformed mental healthcare services, ensuring comprehensive Clinical Psychopharmacology and accessible treatment for patients. as a director and chairman, he has played a key role in shaping policies and treatment methodologies, advocating for holistic mental health approaches. his contributions to medical education have also been instrumental in training the next generation of psychiatrists, sharing his knowledge and clinical insights with aspiring mental health professionals.
🌍 Legacy and future contributions
As a leader in neuropsychiatry, horikoshi continues to shape the future of psychiatric medicine through research, education, and clinical practice. his ongoing commitment to advancing mental health treatments and his efforts in medical education ensure that his impact will be felt for years to come. by mentoring young psychiatrists and fostering collaborations between academic institutions and healthcare facilities, he is paving the way for a new era of neuropsychiatric advancements. his legacy is defined by his unwavering dedication to improving mental health care and his vision for a more comprehensive understanding of psychiatric disorders.
Notable Publications
-
Title: DNA methylation of ANKK1 and response to aripiprazole in patients with acute schizophrenia: A preliminary study
Author(s): I. Miura, Y. Kunii, M. Hino, H. Hoshino, J. Matsumoto, K. Kanno-Nozaki, ...
Journal: Journal of Psychiatric Research
-
Title: COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia
Author(s): H. Kaneko, I. Miura, K. Kanno-Nozaki, S. Horikoshi, M. Hino, H. Yabe
Journal: Neuropsychiatric Disease and Treatment
-
Title: Influence of −141C Ins/Del polymorphism in DRD2 gene on clinical symptoms and plasma homovanillic acid levels in the treatment of schizophrenia with aripiprazole
Author(s): I. Miura, K. Kanno-Nozaki, M. Hino, S. Horikoshi, T. Ota, H. Mashiko, S.I. Niwa, ...
Journal: Journal of Clinical Psychopharmacology
-
Title: Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia
Author(s): K. Watanabe, I. Miura, K. Kanno-Nozaki, S. Horikoshi, H. Mashiko, S.I. Niwa, ...
Journal: Psychiatry Research
-
Title: Lurasidone for the treatment of schizophrenia: design, development, and place in therapy
Author(s): I. Miura, S. Horikoshi, M. Ichinose, Y. Suzuki, K. Watanabe
Journal: Drug Design, Development and Therapy